EDIT Editas Medicine, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR で表示 ↗ 終値 10月 2, 2026 10-K/10-Q 8月 5, 2026
$2.62
· 52週範囲の%
· 安値より上
· 高値へ
$1.6752週安値
$4.5452週高値
時価総額 (MRQ)
$256M
P/E (TTM)
-4.0
EPS (TTM)
$-0.66
収益 (TTM)
$47M
あなたのバッジ
52週レンジ
$2–$5
アナリスト評価
BUY
目標株価
$6
P/E
-4.0
ROE
-118.8%
純利益率
-157.3%
バッジストリップは空です。このページ上の任意の指標をピン留めしてください。
EDIT 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
株価
$2.62
時価総額 (MRQ)
$256M
P/E (TTM)
-4.0
EPS (TTM)
$-0.66
収益 (TTM)
$47M
ROE (TTM)
-118.8%
負債/自己資本 (MRQ)
0.5
52週レンジ
$2–$5
EDIT 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
範囲
バー
バーの粒度は選択した期間に合わせて調整されます。バーの始値/高値/安値/終値を確認するにはチャートにカーソルを合わせてください。
Editas Medicine, Inc. - Common Stock について Wikipediaからの企業概要
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
セクターHealthcare
業種Biotechnology
従業員87
国US
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
収益$41M2016-12-31 → 2025-12-31
EPS$-1.802019-12-31 → 2025-12-31
フリーキャッシュフロー$-166M2016-12-31 → 2025-12-31
純利益率-157.3%2018-12-31 → 2025-12-31
バリュエーションと指標
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
| 指標 | 5年トレンド | EDIT | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| P/E (TTM) | -4.05年平均 ≈-3.7 | ≈-3.7 | · | · | |
| P/S (TTM) | 5.55年平均 ≈24.2 | ≈24.2 | 11.6 | 割安 | |
| 株価純資産倍率 (MRQ) | 2.45年平均 ≈3.1 | ≈3.1 | 2.2 | 割高 | |
| EV / EBITDA (EV/EBITDA) | -1.1 | · | · | · | |
| 株価FCF倍率 (TTM) | -2.15年平均 ≈-4.3 | ≈-4.3 | · | · | |
| 株価収益率（P/CF） (TTM) | -2.15年平均 ≈-4.5 | ≈-4.5 | · | · | |
| EV/売上高 (TTM) | 2.1 | · | · | · | |
| EV/FCF (TTM) | -0.8 | · | · | · | |
| Price / Tangible Book (株価純資産倍率（P/TB）) | 9.45年平均 ≈3.1 | ≈3.1 | · | · |
同業他社の中央値は、指標ごとに標準化された基準で計算されており、この銘柄に表示されているTTM/MRQ基準と常に一致するとは限りません。
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
| 指標 | 5年トレンド | EDIT | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 営業利益率 (TTM) | -161.4%5年平均 ≈-658.2% | ≈-658.2% | -334.4% | トップクラス | |
| EBITDA Margin (EBITDAマージン) | -394.9%5年平均 ≈-658.2% | ≈-658.2% | -334.4% | トップクラス | |
| 純利益率 (TTM) | -157.3%5年平均 ≈-639.3% | ≈-639.3% | -300.0% | トップクラス | |
| ROA (TTM) | -33.0%5年平均 ≈-43.0% | ≈-43.0% | -47.0% | 弱い | |
| ROE (TTM) | -118.8%5年平均 ≈-195.1% | ≈-195.1% | -63.2% | 弱い |
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
| 指標 | 5年トレンド | EDIT | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 負債資本倍率 (MRQ) | 0.5 | · | 0.0 | 高負債 | |
| 流動比率 (MRQ) | 3.25年平均 ≈5.9 | ≈5.9 | 5.6 | 低流動性 | |
| クイックレシオ (MRQ) | 3.15年平均 ≈5.8 | ≈5.8 | 4.2 | 低流動性 | |
| 長期負債/株主資本 (MRQ) | 0.5 | · | · | · |
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
| 指標 | 5年トレンド | EDIT | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Revenue YoY (収益（前年比）) | 25.4%5年平均 ≈33.7% | ≈33.7% | · | · | |
| Revenue CAGR 3Y (収益（3年CAGR）) | 27.2%5年平均 ≈10.1% | ≈10.1% | · | · | |
| Revenue CAGR 5Y (収益（5年CAGR）) | -14.9% | · | · | · |
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
| 指標 | 5年トレンド | EDIT | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Asset Turnover (総資産回転率) | 0.25年平均 ≈0.1 | ≈0.1 | 0.1 | トップクラス | |
| Receivables Turnover (売掛金回転率) | 2.65年平均 ≈6.1 | ≈6.1 | · | · | |
| Revenue / Employee (年間売上高 ÷ 従業員数（yfinanceの報告ヘッドカウント）。派生値 — SEC-XBRLの保存概念ではありません。) | ≈$465.7K | · | · | · |
バリュエーション · ≈ 5年平均 · 業界中央値 · 中央値に対する評価
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
平均サプライズ
2.8%
次回決算
11月 09, 2026
| 期間 | レポート | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|---|
| 2026年6月30日 | 8月 10, 2026 | $-0.15 | $-0.28 | 45.5% |
| 2026年3月31日 | 5月 11, 2026 | $-0.26 | $-0.27 | 3.3% |
| 2025年12月31日 | $-0.06 | $-0.26 | 77.2% | |
| 2025年9月30日 | $-0.28 | $-0.30 | 7.3% | |
| 2025年6月30日 | $-0.63 | $-0.38 | -63.8% | |
| 2025年3月31日 | $-0.92 | $-0.60 | -53.1% |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
貸借対照表
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
キャッシュフロー
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
収益性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
流動性と支払能力
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
効率性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
1株あたり
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | $1.62 | $4.27 | $5.24 | $8.09 | $6.29 | $4.83 | $4.84 | $4.68 | $3.76 | |
| Revenue / Share | $0.46 | $0.39 | $1.03 | $0.29 | $0.38 | · | · | · | · | · | |
| Cash Flow / Share | $-1.86 | $-2.55 | $-1.74 | $-2.58 | $-2.42 | · | · | · | · | · | |
| Cash / Share | $1.50 | $1.59 | $1.51 | $2.06 | $2.97 | $2.23 | $4.38 | $2.76 | $3.29 | $5.17 | |
| EPS (TTM) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · |
成長率
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
バリュエーション（TTM）
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
損益計算書
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $42.0K | $6M | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $41M | $44M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $16M | $17M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $58M | $61M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-58M | $-54M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $1.0K | $235.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-56M | $-53M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.81 | $-0.78 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.81 | $-0.78 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | · | 90,090,397 | 84,412,200 | 83,055,066 | · | 82,485,199 | 82,310,368 | 81,938,839 | · | 81,648,250 | 71,376,678 | 68,924,180 | 68,736,125 | 68,640,858 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | · | 90,090,397 | 84,412,200 | 83,055,066 | · | 82,485,199 | 82,310,368 | 81,938,839 | · | 81,648,250 | 71,376,678 | 68,924,180 | 68,736,125 | 68,640,858 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | $-58M | $-54M |
貸借対照表
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $211M | $169M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | $209M | $283M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | $120.0K | $713.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | $7M | $8M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | $427M | $461M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | $15M | $16M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | $36M | $35M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | $20M | $19M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | $8M | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | $531M | $581M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | $7M | $6M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | $19M | $20M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | $42M | $36M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | $9M | $10M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | $116M | $115M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | $-1.02B | $-962M | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | $-4M | $-3M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $415M | $465M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | $531M | $581M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | 68,761,729 | 68,718,434 |
キャッシュフロー
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $6M | $7M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-48M | $-38M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $614.0K | $632.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $89M | $-4M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $80.0K | $367.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $41M | $-41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
収益性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | -136952.4% | -852.5% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | -132681.0% | -840.2% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | -136952.4% | -852.5% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | -8.9% | -8.0% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | -11.1% | -9.9% |
流動性と支払能力
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | 10.1 | 12.7 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | 9.9 | 12.4 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
効率性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | 0.2 | 12.2 |
1株あたり
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.08 | $0.04 | · | $0.14 | $0.22 | $0.75 | · | $2.13 | $2.81 | $3.58 | · | $4.41 | $4.90 | $4.60 | $6.03 | $6.77 | |
| Revenue / Share | $0.10 | $0.03 | · | $0.08 | $0.04 | $0.06 | · | $0.00 | $0.01 | $0.01 | · | $0.07 | $0.04 | $0.14 | $0.00 | $0.09 | |
| Cash Flow / Share | · | $-0.24 | · | · | · | $-0.58 | · | · | · | $-0.61 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $1.86 | $1.26 | · | $1.78 | $1.59 | $1.66 | · | $1.16 | $0.78 | $0.84 | · | $1.01 | $2.71 | $1.87 | $3.06 | $2.47 | |
| EPS (TTM) | $-0.66 | $-1.14 | · | $-2.38 | $-2.85 | $-3.04 | · | $-2.53 | $-2.33 | $-2.07 | · | $-2.70 | $-2.96 | $-3.18 | $-2.94 | $-2.70 |
バリュエーション（TTM）
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $47M | $39M | · | $46M | $39M | $36M | · | $62M | $67M | $69M | · | $25M | $19M | $23M | $26M | $32M | |
| Net Income TTM | $-74M | $-109M | · | $-200M | $-237M | $-251M | · | $-211M | $-193M | $-166M | · | $-195M | $-206M | $-219M | $-201M | $-184M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | $842M | $813M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -4.9 | -2.2 | · | -1.5 | -0.8 | -0.4 | · | -1.3 | -2.0 | -3.6 | · | -2.9 | -2.8 | -2.3 | -4.2 | -4.4 | |
| P/S | 6.7 | 6.2 | · | 7.0 | 4.9 | 2.7 | · | 4.6 | 5.7 | 8.8 | · | 25.9 | 34.8 | 21.9 | 32.8 | 25.6 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | 2.0 | 1.7 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | 2.0 | 1.7 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| EV / Revenue | 3.4 | 4.5 | · | 4.7 | 1.8 | -1.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -20.4% | -46.2% | · | -68.6% | -129.6% | -262.1% | · | -74.2% | -49.9% | -27.9% | · | -34.6% | -36.0% | -43.9% | -24.0% | -22.8% |
最新期間は左側 · null値は・として表示
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 収益 | $41M | $32M | $78M | $20M | $26M |
| 営業利益率 % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| 純利益 | $-160M | $-237M | $-153M | $-220M | $-193M |
| 希薄化後EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 負債資本倍率 | 2.1 | 0.4 | · | · | · |
| 流動比率 | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| クイックレシオ | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $-166M | $-219M | $-137M | $-181M | $-172M |
機関投資家（13F） 236 提出者 · $406.3M合計 · 時点 2026年9月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
保有者
236
保有価値
$406.3M
新規ポジション
38
解消済みポジション
23
機関投資家の動向 — Q2 2026 対 前四半期
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 38 (-7 前期比) | 23 (-3 前期比) | 80 (+22 前期比) | 42 (-8 前期比) | +68.9M |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36,000,000 | 11,111,111 | 8.86% | 株式数 |
| BlackRock, Inc. | $34,311,568 | 10,589,990 | 8.44% | 株式数 |
| RA CAPITAL MANAGEMENT, L.P. | $28,800,360 | 8,889,000 | 7.09% | 株式数 |
| Commodore Capital LP | $28,800,360 | 8,889,000 | 7.09% | 株式数 |
| ADAR1 Capital Management, LLC | $28,800,360 | 8,889,000 | 7.09% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $19,897,929 | 6,141,336 | 4.90% | 株式数 |
| Paradigm Biocapital Advisors LP | $18,100,665 | 5,586,625 | 4.45% | 株式数 |
| VANGUARD GROUP INC | $16,826,539 | 8,208,068 | 4.14% | 株式数 |
| Opaleye Management Inc. | $12,512,653 | 3,861,930 | 3.08% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11,658,618 | 3,598,339 | 2.87% | 株式数 |
| Woodline Partners LP | $11,519,810 | 3,555,497 | 2.84% | 株式数 |
| Vivo Capital, LLC | $11,519,010 | 3,555,250 | 2.83% | 株式数 |
| GordonMD Global Investments LP | $10,131,480 | 3,127,000 | 2.49% | 株式数 |
| GOLDMAN SACHS GROUP INC | $8,469,476 | 2,614,036 | 2.08% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $8,325,643 | 2,569,072 | 2.05% | 株式数 |
| RENAISSANCE TECHNOLOGIES LLC | $7,999,298 | 2,468,919 | 1.97% | 株式数 |
| Logos Global Management LP | $7,199,280 | 2,222,000 | 1.77% | 株式数 |
| STATE STREET CORP | $7,101,442 | 2,191,803 | 1.75% | 株式数 |
| MARSHALL WACE, LLP | $6,600,808 | 2,037,287 | 1.62% | 株式数 |
| D. E. Shaw & Co., Inc. | $6,159,246 | 1,901,002 | 1.52% | 株式数 |
| JPMORGAN CHASE & CO | $5,959,980 | 1,862,494 | 1.47% | 株式数 |
| AQR CAPITAL MANAGEMENT LLC | $5,094,065 | 1,572,242 | 1.25% | 株式数 |
| TWO SIGMA INVESTMENTS, LP | $4,318,842 | 1,332,976 | 1.06% | 株式数 |
| Seven Fleet Capital Management LP | $4,310,820 | 1,330,500 | 1.06% | 株式数 |
| RAYMOND JAMES FINANCIAL INC | $4,273,389 | 1,318,947 | 1.05% | 株式数 |
| KENNEDY CAPITAL MANAGEMENT LLC | $3,344,111 | 1,032,133 | 0.82% | 株式数 |
| MACKENZIE FINANCIAL CORP | $2,844,856 | 878,042 | 0.70% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2,812,424 | 868,032 | 0.69% | 株式数 |
| Nantahala Capital Management, LLC | $2,762,748 | 852,700 | 0.68% | 株式数 |
| NORTHERN TRUST CORP | $2,655,806 | 819,693 | 0.65% | 株式数 |
| TWO SIGMA ADVISERS, LP | $2,509,405 | 1,224,100 | 0.62% | 株式数 |
| UBS Group AG | $2,432,472 | 750,763 | 0.60% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $2,407,158 | 742,950 | 0.59% | 株式数 |
| Nuveen, LLC | $1,688,730 | 521,213 | 0.42% | 株式数 |
| MILLENNIUM MANAGEMENT LLC | $1,616,750 | 498,997 | 0.40% | 株式数 |
| Susquehanna Portfolio Strategies, LLC | $1,545,801 | 477,099 | 0.38% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,521,180 | 469,500 | 0.37% | コールオプション |
| Eversept Partners, LP | $1,486,541 | 458,809 | 0.37% | 株式数 |
| Casdin Capital, LLC | $1,441,800 | 445,000 | 0.35% | 株式数 |
| PEAK6 LLC | $1,346,029 | 415,441 | 0.33% | 株式数 |
| DIADEMA PARTNERS LP | $1,296,000 | 400,000 | 0.32% | コールオプション |
| MORGAN STANLEY | $1,108,616 | 342,165 | 0.27% | 株式数 |
| BIT Capital GmbH | $1,056,240 | 326,000 | 0.26% | 株式数 |
| WELLINGTON MANAGEMENT GROUP LLP | $1,002,440 | 309,395 | 0.25% | 株式数 |
| Cubist Systematic Strategies, LLC | $994,094 | 286,482 | 0.24% | 株式数 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878,642 | 271,186 | 0.22% | 株式数 |
| Bank of New York Mellon Corp | $850,907 | 262,625 | 0.21% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $751,119 | 231,827 | 0.18% | 株式数 |
| LPL Financial LLC | $748,813 | 231,115 | 0.18% | 株式数 |
| Erste Asset Management GmbH | $736,000 | 230,000 | 0.18% | 株式数 |
アクティビストおよび5%超のオーナー 1保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 提出書類 | 2017年9月18日 | · | 初回提出 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
企業インサイダー 35 人のインサイダー · 17人の役員 · 17人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 2026年9月3日 S | 243,189 | 0 | 4 | $-80,045 |
| MULLEN JAMES C | CEO | 2022年4月14日 A | 75,898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 2021年2月9日 S | 43,760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 2019年1月8日 S | 1,204,966 | 0 | 0 | $0 |
| Amy Parison | SVP, Chief Financial Officer | 2026年9月3日 S | 13,839 | 0 | 5 | $-6,327 |
| Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | 2025年3月8日 A | 112,720 | 0 | 0 | $0 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | 2023年5月11日 S | 106,610 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 2019年2月4日 M | 0 | 0 | 0 | $0 |
| Daniel Scott Ory | EVP, Chief Medical Officer | 2026年9月8日 A | · | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 2026年9月3日 S | 61,660 | 0 | 5 | $-20,333 |
| Baisong Mei | EVP, CHIEF MEDICAL OFFICER | 2024年12月3日 S | 133,354 | 0 | 0 | $0 |
| Bruce Eaton | EVP, CBO AND CTO | 2023年12月5日 S | 74,791 | 0 | 0 | $0 |
| Mark S Shearman | EVP, CHIEF SCIENTIFIC OFFICER | 2023年2月13日 S | 65,559 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 2021年12月22日 A | 22,675 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 2019年10月28日 A | 25,000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 2019年3月18日 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 2018年2月7日 A | 4,000 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | 取締役 | 2026年8月6日 A | · | 0 | 0 | $0 |
| Elliott M. Levy | 取締役 | 2026年6月17日 A | · | 0 | 0 | $0 |
| David Scadden | 取締役 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Bernadette Connaughton | 取締役 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Jessica Hopfield | 取締役 | 2026年6月17日 A | 67,700 | 0 | 0 | $0 |
| Andrew Hirsch | 取締役 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Meeta Chatterjee | 取締役 | 2024年5月30日 A | · | 0 | 0 | $0 |
| Emma Reeve | 取締役 | 2024年5月30日 A | · | 0 | 0 | $0 |
| Akshay Vaishnaw | 取締役 | 2024年5月30日 A | · | 0 | 0 | $0 |
| Boris Nikolic | 取締役 | 2018年6月15日 A | 35,000 | 0 | 0 | $0 |
| Douglas G. Cole | 取締役 | 2017年8月17日 J | 3,171 | 0 | 0 | $0 |
| Kevin Bitterman | 取締役 | 2017年6月15日 A | 2,797,144 | 0 | 0 | $0 |
| Alexis Borisy | 取締役 | 2017年6月15日 A | 0 | 0 | 0 | $0 |
| John Mendlein | 取締役 | 2017年6月15日 A | · | 0 | 0 | $0 |
| Kevin P Starr | 10%オーナー | 2016年9月6日 S | 0 | 0 | 0 | $0 |
| bng0, LLC | 10%オーナー | 2016年2月8日 C | 2,649,572 | 0 | 0 | $0 |
| Charles Albright | · | 2020年12月15日 M | 24,907 | 0 | 0 | $0 |
| Alexandra Glucksmann | · | 2017年3月15日 M | 117,788 | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
ETF保有状況 17のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.43% | 39,171 SH | 2026年10月2日 | 日次 |
| IWC · iShares Trust | 0.06% | 339,728 SH | 2026年9月11日 | 日次 |
| IBB · iShares Trust | 0.03% | 1,101,092 SH | 2026年9月11日 | 日次 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.03% | 11,076 SH | 2026年10月1日 | 日次 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.02% | 96,927 SH | 2026年8月19日 | 日次 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 170,052 SH | 2026年10月2日 | 日次 |
| IWO · iShares Trust | 0.02% | 844,017 SH | 2026年9月11日 | 日次 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 575,834 SH | 2026年8月19日 | 日次 |
| VHT · VANGUARD WORLD FUND | 0.01% | 461,967 SH | 2026年8月19日 | 日次 |
| IWM · iShares Trust | 0.01% | 2,588,297 SH | 2026年9月11日 | 日次 |
| RSSL · Global X Funds | 0.01% | 47,823 NS | 2026年7月31日 | N-PORT |
| IWV · iShares Trust | 0.00% | 19,230 SH | 2026年9月11日 | 日次 |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 1,100,306 SH | 2026年8月19日 | 日次 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 4,890,144 SH | 2026年8月19日 | 日次 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.00% | 9,046 SH | 2026年8月19日 | 日次 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 7,608 SH | 2026年8月19日 | 日次 |
| IWN · iShares Trust | · | 120,579 SH | 2026年9月11日 | 日次 |
EDIT アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
レーティング · 18 アナリスト
買い
中央値ターゲット
$5.00
+90.8%
5 27.8%
強い買い
7 38.9%
買い
4 22.2%
保有
2 11.1%
売り
0 0.0%
強い売り
12ヶ月目標株価
10 アナリスト · 2026-09-27平均値ターゲット $5.90 +125.2%
現在
現在価格 $2.62
安値$1.00
平均値$5.90
高値$15.00
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
FY基準、価格は各社の直近年度末終値。
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| RZLT | $501M | -6.9 | · | · | -67.8% | · |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| CCCC | $185M | -1.5 | 1.0% | -292.1% | -48.8% | · |
| EIKN | · | · | · | · | · | · |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
| AGEN | $111M | · | 10.4% | -2.7% | 1.0% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
重視する指標を選択してください — 上記の「財務諸表」の任意の行の横にある「+」をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
出典：SEC 10-Q 提出日 8月 5, 2026